Allergy Therapeutics plc (AGY.L)
LSE · GBp · Healthcare · Drug Manufacturers - Specialty & Generic
£4.25 (+0.00%) as of
Key statistics
- Market cap
- 269.13M
- Forward P/E
- -5.90
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 4.0000 – 12.1000
- Beta
- 0.92
- Revenue (TTM)
- 57.29M
- Profit margin
- -84.08%
- Analyst target
- £13.00
- Volume
- 326.53k
About Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Worthing, United Kingdom
- Employees
- 584
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.